Attwells, Sophia
Setiawan, Elaine
Rusjan, Pablo M.
Xu, Cynthia
Kish, Stephen J.
Vasdev, Neil
Houle, Sylvain
Santhirakumar, Apitharani
Meyer, Jeffrey H. http://orcid.org/0000-0003-4684-5052
Funding for this research was provided by:
Gouvernement du Canada | Instituts de Recherche en Santé du Canada | CIHR Skin Research Training Centre
Article History
Received: 6 July 2020
Revised: 30 March 2021
Accepted: 30 April 2021
First Online: 29 May 2021
Conflict of interest
: The corresponding author (J.H.M.) has been a consultant to Lundbeck and Takeda, in the past 5 years. J.H.M. is an inventor on five patents of blood and/or clinical markers to predict brain inflammation or to diagnose affective disorders, and a dietary supplement to reduce depressed mood postpartum. J.H.M. is receiving operating grant funding from Sanofi for a neuroinflammation PET imaging study in multiple sclerosis. J.H.M. is arranging collaborations with nutraceutical companies for the dietary supplement to prevent postpartum depression. S.K. has operating grant funds from US National Institutes of Health National Institute on Drug Abuse (DA04066) to measure microglial status in the brains of methamphetamine users, and from Jazz Pharmaceuticals for an unrelated study. All other authors declare no conflicts of interest.